The objective of generic drug policies in most countries is defined from a disinvestment perspective: reduction in expenditures without compromising health outcomes. However, in countries with restricted access of patients to original patented drugs, the objective of generic drug policies can also be defined from an investment perspective: health gain by improved patient access without need for additional health budget.
Introduction
The main policy objective of health care decision-makers is to maximize health gain for the population by efficiently allocating limited resources [1] . Off-patent medicines, such as generic and biosimilar medicines, can support this objective by offering equally high-quality treatment at lower costs [2] [3] .
An increased use of generic medicines can generate significant savings in the health care budget [3] [4] [5] [6] .
The objective of generic drug policies is usually defined as reduction in expenditures without compromising health outcomes [7] .
However, the objective of generic drug policies can be defined differently in countries with significant resource constraints, where the accessibility of patients to high-cost patented medicines may be limited. In these countries third-party payers implement different cost-containment measures, including incentives to different stakeholders to restrict the utilization of high-cost medicines [8] .
Volume limits for individual physicians or health care institutions may prevent prescribers to propose the most optimal drug therapy for all eligible patients. Alternatively, high-cost medicines may be reimbursed only as second-line therapies after the failure of first-line therapies. Significant copayment can increase the price sensitivity of patients, and therefore limit their accessibility to high-cost medicines compared to the full reimbursement scenario. Payback mechanisms may reduce the profitability of manufacturers with increased drug utilization, and therefore create disincentives to promotional activities.
Such restrictions may be alleviated due to generic price erosion, and consequently patient access can be improved significantly after patent expiry [9] . In such cases the most important benefit of generic medicines is not cost-savings, but increased health gain. In countries with restricted access of patients to original patented medicines the objective of generic drug policies can be also defined from an investment perspective: health gain by improved patient access without need for additional health budget [7] . The majority of scientific publications support the cost-saving potential of generic medicines [10] [11] [12] , but empirical evidence related to increased patient access is limited [13] .
Our objective was to explore whether increased utilization of clopidogrel after the market entry of generic medicines is associated with affordability constraints (i.e. GDP per capita) in European countries. Clopidogrel is used to prevent problems caused by blood clots in patients with significant risk for vascular events, such as recent myocardial infarction or stroke, established peripheral arterial disease, acute coronary syndrome [14] .
We selected clopidogrel based on several criteria. Firstly, patent expiry between 2005 and 2010 ensured that we had sufficient follow-up period after the entry of first generic alternatives in major European countries. Secondly, significant health gain of clopidogrel (i.e. >0.1 QALYs) compared to previous standard therapies was calculated in several studies [15] [16] [17] [18] [19] , hence we assumed that increased patient access could be translated to health gain. Thirdly, clopidogrel was a first-in-class product with no relevant therapeutic alternatives, therefore increased utilization after patent expiry could not be related to cannibalization of the market share of similar products. Finally, clopidogrel is mainly distributed through retails pharmacies, and so the IMS database could provide reliable longitudinal data on sales volumes.
Data and methods

Data
We made use of detailed product-level clopidogrel sales data that were provided to us by IMS Health.
The database of our analysis contained quarterly sales information of clopidogrel products (measured in standard units) between 2004 and 2014 from 27 countries (all members of the European Union except Croatia, Cyprus and Malta, together with Norway and Switzerland). Cyprus and Malta were not present in the original database, and we omitted Croatia, Russia and Turkey because -for Croatia -no data were available before the generic entry and -for the two other countries -regulatory practice and economic development differed much from the other part of the sample. Name, manufacturer, strength (mostly 75 mg and sometimes 300 mg) and generic / non-generic category were also shown for the products in the database.
In our analysis we used a country-and annual-(or quarter-) level longitudinal database aggregated from the product-level data. The dependent variable was the aggregated DOT (days of treatment) sales of clopidogrel, divided by the population of the country. DOT sales were obtained by multiplying standard units by strength and dividing by the DDD (daily defined dose) of 75 mg.
The main explanatory variables of interest were 1) the binary variable indicating the periods after the first appearance of a generic clopidogrel product in the given country, and 2) the number of different generic manufacturers in the given country in the given year. We also used control variables that describe affordability, health need and priorities for health care in a country, hence may influence drug utilization. Taking into account the time series availability of the data and the indications for clopidogrel, we measured these factors with GDP per capita in PPP, the health expenditure per GDP ratio, the proportion of old-age population (above 65 years) and the age-standardized death rate (SDR) from diseases of circulatory system (for all ages). The latter variable was not available after 2012 and for some other sporadic country-years hence its missing values were imputed by simple country-specific log-linear trends. The source of data was World Bank and -for SDR from circulatory diseases -the HFA-WHO database. We note that, not surprisingly, the parameter estimates of our interest do not change if we use health expenditure per capita instead of the health expenditure per GDP ratio in the equations.
Descriptive analysis
The first generic clopidogrel product entered the market in 2009 in the majority of countries (20 Most countries experienced a monotonous increase in the generic share after the generic entry. Notable exceptions are Bulgaria, Norway and Slovenia, where generic clopidogrel was temporarily removed from the market after its first introduction because of patent problems (see Baumgartel et al. [20] for details of these events). Due to these specific events these three countries were omitted from the regression analysis below. Luxemburg was also omitted because of its small size and its special relationship with Belgium with regard to pharmaceutical sales.
There was also a small temporary decrease in the generic ratio in France around 2010-2011 becauseas the French Competition Authority later ruled and issued a fine for it -the drug maker Sanofi encouraged a campaign to discourage doctors and pharmacists from prescribing or substituting generic versions of its former clopidogrel product Plavix. After the resolution of this issue the generic share in Before a more formal analysis, Table 1 was even negatively correlated with utilization in this period, suggesting that these variables are not necessarily good proxies for health (clopidogrel) need.
( Table 1 about 
Methods
Based on the above considerations, we analyzed the longitudinal (panel) clopidogrel utilization data of European countries with a multilevel model (a random intercept -random slope model). These models (also known as hierarchical models) are appropriate to describe the country-specific random trends of clopidogrel utilization, whilst controlling for multiple confounding variables (see e.g. Gelman and Hill [21] , for a general review, and Rice and Jones [22] , for an early health-specific review of such models). In our analysis we used the following baseline specification: The country-specific trend, defined in equation (3), depends on and thus its parameter 1 measures the trend difference between the lower-and higher-income countries. We expect 1 < 0 because, on average, lower-income European countries experienced a faster growth rate of clopidogrel utilization than higher-income ones (Figure 1 ). Finally, equation (1) contains a general quadratic trend in clopidogrel utilization to allow for a possible saturation effect in the given period. We expect , the parameter of the quadratic trend, to be slightly negative.
The multilevel structure of the model implies that the country-level intercept and the time trend vary by country beyond the mere effect of the control variables (equations (2)-(3)). The usual multilevel modelling assumptions apply for the three error terms of the model ( , , ).
Beyond the baseline model we used two alternative specifications. In the second specification, we restricted the estimation sample to a six-year wide (i.e. ±3 years) time window around the generic entry. By concentrating on periods just preceding and following generic entry, possible longer-term nonlinear trends or longer-term confounding factors could be ruled out. Also, to get rid of possible discrepancies in clopidogrel sales just before the time of generic entry, we omitted the year of generic entry from the sample in this specification.
In the third specification we examined in more detail which aspects of the generic entry affected clopidogrel utilization. We added two more variables to equation (1): the year of generic entry in country relative to the last quarter of 2009, denoted by , and the logarithm of the number of generic manufacturers in country in year , relative to the average number of generic manufacturers after the generic entries (this logarithmic difference is denoted by ). Hence our equation (1) became (1') Y it = α i + τ i * t + θ * t 2 + (β 0 + β 1 * Z i + β 2 * R i + β 3 * M it ) * Aft it + it + ε it .
If earlier generic entry was associated with a larger increase in utilization then β 2 < 0. If the number of generic manufacturers increased clopidogrel utilization then β 3 > 0. Table 2 shows the parameter estimates of the multilevel models. According to our baseline specification (first column of Table 2 ) the generic entry had an essentially zero effect on the level of clopidogrel utilization for the highest-income countries (̂0 = −0.02 in equation (1) Among the four control variables the logarithm of per capita GDP and the health expenditure per GDP ratio were significant. On average, in the given period, a one per cent larger GDP per capita was associated with an around 2.2 per cent larger per capita clopidogrel utilization (95% confidence interval: 0.9-3.5 per cent). However, since the country-specific trends strongly depended on income (see Figure 1 and Table 2 ), this relationship holds only on average. As shown in the descriptive analysis the relationship was very strongly positive at the beginning of the period and decayed until 2014 (see Figure 2 ). Finally, holding per capita GDP and other factors fixed, a one percentage point larger health expenditure per GDP ratio was associated with 8 per cent larger per capita clopidogrel utilization, suggesting that this variable is an appropriate, partially independent proxy of health need, affordability and priorities for health care. The parameters of the two other control variables (proportion of old-age population and SDR from circulatory diseases) were not significant.
Results
The conclusions of the second specification, where the model was estimated on the restricted sample, are similar to the baseline results (see the second column of Table 2 ). The third specification (the third column of Table 2 ), in which we modeled further heterogeneous effects of the generic entry, shows that a one year earlier appearance of generic versions increased clopidogrel utilization by about 100×(exp(0.29)-1)=34 per cent (̂2 = −0.29) and this effect was highly significant. Since this result was mainly governed by the lower-income country Poland, where generic entry occurred in 2006
(much earlier than in other countries in the sample), the interaction term with logarithmic GDP per capita was lower in magnitude (̂1 = −0.52) in this specification than in the baseline onenevertheless it was still significant at the 5 per cent level. The specification also shows that the number of generic manufacturers was not significantly associated with the increase of clopidogrel utilization after the generic entry.
( Table 2 about here)
Discussion and conclusions
In this paper we analyzed the determinants of clopidogrel utilization in European countries between 2004 and 2014. We found that clopidogrel utilization was strongly affected by affordability constraints (as proxied by GDP per capita) before entrance of generic medicines but this effect decayed by 2014.
In line with this, our estimated models found a substantially larger trend increase of clopidogrel utilization in lower-income European countries than in the highest-income ones.
Similarly, the evidence shows that entry of generic medicines increased clopidogrel consumption in lower-and average-income countries but not in the highest-income ones. The data also suggest that an earlier generic entry was associated with a larger effect.
Although we could exploit the variation in the time of generic entry across countries in our estimation strategy, our results were mainly driven by the comparison of clopidogrel utilization levels and trends before and after 2009, the year of generic entry in most countries. Although we controlled for various confounding variables and for a saturation effect in the data, it is still possible that our results were partly governed by external factors we could not control for. In the future it would be worth investigating other pharmaceuticals as well, for which the variation of the time of generic entry was larger, because exploiting this variation would lead to more precise estimates of the effects of generic entry. A similar analysis of 35 generic medicines was carried out by Dylst and Simoens [4] , but they focused on the relationship between market share and the price level.
Our research is related to a neglected area, as evaluation of generic drug policies is not a popular field of health policy research. Pharmaceutical policy makers put more emphasis on improving policies of innovative medicines due to pressure from patients, health care professionals and manufacturers to increase patient access to novel therapies. However, the success of public health policies is more dependent on the efficiency of generic drug policies since in disease areas with the most public health burden, such as cardiovascular diseases, the first line treatments are already generic medicines [7] .
Hence the importance of generic drug policies has been increasing over time. Generic medicines can improve the sustainability of financing pharmaceuticals by generating savings in health care systems.
In addition, off-patent drugs may also generate health gain by improving the accessibility of patients to medicines, especially in countries with cost-containment measures. If volume restrictions were applied for individual prescribers or health care institutions, with generic entry more patients can be treated from the same budget. As generics are more cost-effective than originator medicines, payers may allow first line use of effective generic drugs, if second-line restriction for the originator product in the therapeutic guidelines was implemented only due to economic reasons. Generic price erosion can also result in reduced copayment that may diminish disincentives of patients to access to the most appropriate therapies.
In those countries where cost-containment measures are applied for the originator product payers should equally understand the population health gain and savings in the health care budget due to increased utilization of generic drugs. Patient adherence and persistence are important factors of health gain in chronic diseases, however, policymakers rarely consider these indicators when evaluating generic drug policies, often they just focus on facilitating generic price erosion.
The case of clopidogrel indicates that the utilization of effective patented medicines is affected by affordability constraints. The entrance of generics, however, may increase patient access and improve health outcomes, most notably in lower income countries, thereby reducing inequalities between European patients.
Our results highlighted that for lower income countries the investment aspect of generic drug policies can be equally or even more important than the aspect of disinvestment. Policymakers should also consider this investment aspect of generic medicines when designing and implementing European and national pharmaceutical policies. 
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